Nephrolyx
Nephrolyx GmbH is a Berlin-based diagnostics company that provides CE-marked Nephrolyx IVDx (iohexol IVD kit plus GFRx LIMS-integrated software) and the DNPx research platform for measured Glomerular Filtration Rate (mGFR) kidney function testing, serving clinical laboratories, physicians, hospitals, and pharma/biotech research customers across EMEA.
- Company typePrivate
- Founded2012
- HeadquartersBerlin, Germany
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
What Nephrolyx does
Nephrolyx GmbH is a Berlin-based diagnostics company that develops measured Glomerular Filtration Rate (mGFR) testing solutions for kidney function assessment. Its core product, Nephrolyx IVDx, combines a CE-marked in vitro diagnostic (IVD) iohexol-based kit with a digital GFRx software module that integrates into customer Laboratory Information Management Systems (LIMS) and computes mGFR via pharmacokinetic algorithms from (U)HPLC measurement data. The company also offers DNPx, a digital nephrology platform for research use supporting both multi-sample and single-sample protocols. The underlying technology leverages 12 years of research conducted at Charité Universitätsmedizin Berlin and is positioned as a more accurate, cost-effective, and rapid (<6-hour turnaround) alternative to existing mGFR methods such as 99mTc-DTPA and lab-developed tests, as well as biomarker-based estimated GFR (eGFR) approaches.
The company serves clinical laboratories with UHPLC/HPLC capabilities, physicians and nephrologists, hospitals and ambulatory care settings, and pharma/biotech companies conducting kidney research and clinical trials. Revenue is generated through IVD kit sales, software licensing/subscription for the GFRx module and DNPx platform, and professional services or research-collaboration arrangements with pharmaceutical sponsors. Pricing is quote-based and not publicly disclosed; go-to-market is enterprise field sales supported by a 2-week demo trial, with primary marketing channels being the corporate website, LinkedIn, and earned media in German outlets such as Der Tagesspiegel and Adlershof news. Funding to date has come entirely from a non-dilutive ERDF/State of Brandenburg ProFIT grant (NephroAL project); no institutional venture equity is disclosed. Leadership is led by Managing Director Dr. Markus Riester, with operations across Berlin-Adlershof and Wildau, Germany.
Geographically, Nephrolyx is CE-marked for the European market and explicitly not available for clinical diagnostic use in the United States, with EMEA as the disclosed served market. The company has 1-10 employees and operates as an independent, founder-driven German private limited liability company.
Nephrolyx firmographics
Firmographics- Name
- Nephrolyx
- Legal name
- Nephrolyx GmbH
- Website
- https://nephrolyx.com
- Company type
- Private
- Founded year
- 2012
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Nephrolyx GmbH is a Berlin-based diagnostics company that provides CE-marked Nephrolyx IVDx (iohexol IVD kit plus GFRx LIMS-integrated software) and the DNPx research platform for measured Glomerular Filtration Rate (mGFR) kidney function testing, serving clinical laboratories, physicians, hospitals, and pharma/biotech research customers across EMEA.
- Ownership category
- akta.pro rank
Nephrolyx industry classification
Industry- Product category
- Clinical Kidney Function Diagnostics
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)
- akta.pro primary industry
- Renal Diagnostics & Monitoring (eGFR/Creatinine POC, Urine Analyzers, BP/Fluid Status) (HLAHAKAJ)
Keywords
Where Nephrolyx is headquartered
LocationHeadquarters
- HQ city
- Berlin
- HQ country
- Germany
- HQ region
- Europe
Offices2 records
Markets served
Nephrolyx business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Revenue model
- IVD Kit Sales: Sale of IVD kits for clinical kidney function diagnostics. Nephrolyx IVDx combines an IVD kit with a digital software module.
- Software Licensing (GFRx/DNPx): Digital GFRx software module for clinical use integrated into LIMS systems, and DNPx digital platform for research use. Software modules likely sold through licensing or subscription model.
- Pharma/Biotech Research Support: Supporting pharma and biotech companies in kidney research and clinical trials, likely through service or licensing arrangements.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Enterprise/Laboratory pricing - quote-based |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Nephrolyx product offering
Product offeringCore offering
Nephrolyx develops and sells the Nephrolyx IVDx, a CE-marked in vitro diagnostic (IVD) kit combined with a digital GFRx software module for measuring Glomerular Filtration Rate (mGFR) using iohexol-plasma-clearance in clinical routine. The software integrates into laboratory LIMS systems and is designed for semi-automatic processing on UHPLC/HPLC devices. For research use, Nephrolyx offers the DNPx Digital Nephrology Platform, which calculates mGFR via pharmacokinetic algorithms from iohexol concentrations obtained through (U)HPLC measurements.
Product overview
Nephrolyx offers a dual-product portfolio centered on kidney function diagnostics. The core clinical product is Nephrolyx IVDx, which combines an IVD kit with the GFRx software module for measured Glomerular Filtration Rate (mGFR) determination using iohexol plasma clearance in clinical routine settings. For research applications, the company provides DNPx (Digital Nephrology Platform), a software platform that calculates GFR using pharmacokinetic algorithms with support for multiple and single-sample protocols. The IVDx is designed for laboratories using semi-automatic UHPLC or HPLC processing, while DNPx is positioned for research use only.
Differentiator
Problem solved
Functional benefit
Products and services
- Nephrolyx IVDx A CE-marked in vitro diagnostic (IVD) kit combined with a digital GFRx software module for measuring Glomerular Filtration Rate (mGFR) using iohexol plasma clearance in clinical routine. Designed for laboratory settings using semi-automatic processing in UHPLC or HPLC devices. The GFRx software module integrates into LIMS systems for automated GFR reporting.
- DNPx (Digital Nephrology Platform) A digital research-use platform that calculates Glomerular Filtration Rate (GFR) using pharmacokinetic algorithms from iohexol concentrations obtained through (U)HPLC measurements. Supports both multiple-sample protocols (two-sample minimum) and single-sample protocols. Available for research use only, with a 2-week online demo trial offered.
Quantifiable outcome
- Same-day clinical results with turnaround time under 6 hours
- +3 more outcomes
Companies that use Nephrolyx
Customer profileNamed customers4 records
Segments4 records
Ideal customer profiles3 records
Nephrolyx technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
Feature4 records
Nephrolyx partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Charité Universitätsmedizin Berlincore12-year research partnership foundational to company creation. Company builds on extensive research in kidney function diagnostics at one of Europe's leading university hospitals. Research background underpins all proprietary technology development.
Scale indicators3 records
Recent moves4 records
Expansion highlights4 records
Nephrolyx competitors and assessment
Company assessmentDirect peers
- MediBeacon: MediBeacon is developing transdermal, fluorescent iohexol-based mGFR measurement (TGFR), making it the closest methodological and clinical peer to Nephrolyx in commercializing iohexol gold-standard GFR testing outside the laboratory.
- BioPorto Diagnostics: BioPorto commercializes NGAL-based acute kidney injury diagnostics (e.g., The NGAL Test) and other kidney-injury biomarkers, serving overlapping nephrology and clinical-laboratory customers with adjacent renal-diagnostic products.
Broad incumbents
- Siemens Healthineers: Siemens Healthineers runs a broad clinical-chemistry/immunoassay portfolio (Atellica, ADVIA Centaur) used by the same clinical labs Nephrolyx targets, and could either compete in or provide the platform through which mGFR is ultimately delivered.
- Roche Diagnostics: Roche is the global IVD leader (cobas platforms) serving hospital and reference labs with broad renal-function chemistry menus, making it the principal scale competitor for any routine kidney-function assay adoption.
- Abbott Diagnostics: Abbott's diagnostics arm (ARCHITECT, Alinity ci) supplies clinical chemistry assays including renal panels to the same hospital and reference-lab customer base, positioning it as a broad incumbent that could bundle or compete with mGFR assays.
- Beckman Coulter (Danaher): Beckman Coulter offers DxC/AU clinical chemistry platforms widely deployed in routine hospital laboratories, representing both a competing platform route and a potential partnership/distribution channel for kidney-function assays.
- DiaSorin: DiaSorin is a specialty diagnostics player with a strong European footprint in clinical and specialty immunoassays, overlapping with Nephrolyx's nephrology-focused clinical-laboratory channel.
- Fresenius Medical Care: As the global dialysis and integrated kidney-care leader, Fresenius Medical Care is a structural buyer/partner candidate for any technology that improves precision of renal-function assessment in CKD and dialysis patients.
- EUROIMMUN (PerkinElmer/Revvity): EUROIMMUN/Revvity operates specialty autoimmune and kidney-disease assay lines across European clinical labs, overlapping with the nephrology diagnostics audience Nephrolyx is approaching.
Others
- Bayer (Radiology / Contrast Media): Bayer markets iohexol (Omnipaque), the upstream contrast/filtration marker used in Nephrolyx's chemistry, making it a key upstream relationship and potential strategic partner in clinical and research supply.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Nephrolyx social profiles
Digital presenceNephrolyx compliance and trust
Trust signalCompliance1 record
Nephrolyx financial estimates
Financial estimateRevenue estimate
Valuation estimate
Nephrolyx leadership team
Management profileNumber of profiles
Profiles1 record
Nephrolyx funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Nephrolyx M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Nephrolyx
What does Nephrolyx do?
Nephrolyx develops and sells the Nephrolyx IVDx, a CE-marked in vitro diagnostic (IVD) kit combined with a digital GFRx software module for measuring Glomerular Filtration Rate (mGFR) using iohexol-plasma-clearance in clinical routine. The software integrates into laboratory LIMS systems and is designed for semi-automatic processing on UHPLC/HPLC devices. For research use, Nephrolyx offers the DNPx Digital Nephrology Platform, which calculates mGFR via pharmacokinetic algorithms from iohexol concentrations obtained through (U)HPLC measurements.
Is Nephrolyx a public or private company?
Nephrolyx is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Nephrolyx founded?
Nephrolyx was founded in 2012. It employs 1 to 10 people.
Where is Nephrolyx based?
Nephrolyx is headquartered in Berlin, Germany, in the Europe region.
How does Nephrolyx make money?
Three revenue lines are on record. IVD Kit Sales are the primary driver. The others are software Licensing (GFRx/DNPx) and pharma/Biotech Research Support.
Who are Nephrolyx's main competitors?
Direct peers on record are MediBeacon and BioPorto Diagnostics. Broad incumbents are Siemens Healthineers, Roche Diagnostics, Abbott Diagnostics, Beckman Coulter (Danaher), DiaSorin, Fresenius Medical Care and EUROIMMUN (PerkinElmer/Revvity). Bayer (Radiology / Contrast Media) is listed as an others.
Does Nephrolyx have an API?
No public API is recorded for Nephrolyx.
What industry is Nephrolyx in?
Nephrolyx's product category is Clinical Kidney Function Diagnostics. Its primary akta.pro industry code is HLAHAKAJ, Renal Diagnostics & Monitoring (eGFR/Creatinine POC, Urine Analyzers, BP/Fluid Status). Its NAICS code is 325413 and its SIC code is 2835.